Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers
Ryszard M Pluta, Edward H Oldfield, Kamran D Bakhtian, Ali Reza Fathi, René K Smith, Hetty L Devroom, Masoud Nahavandi, Sukyung Woo, William D Figg, Russell R Lonser, Ryszard M Pluta, Edward H Oldfield, Kamran D Bakhtian, Ali Reza Fathi, René K Smith, Hetty L Devroom, Masoud Nahavandi, Sukyung Woo, William D Figg, Russell R Lonser
Abstract
Background: Infusion of sodium nitrite could provide sustained therapeutic concentrations of nitric oxide (NO) for the treatment of a variety of vascular disorders. The study was developed to determine the safety and feasibility of prolonged sodium nitrite infusion.
Methodology: Healthy volunteers, aged 21 to 60 years old, were candidates for the study performed at the National Institutes of Health (NIH; protocol 05-N-0075) between July 2007 and August 2008. All subjects provided written consent to participate. Twelve subjects (5 males, 7 females; mean age, 38.8±9.2 years (range, 21-56 years)) were intravenously infused with increasing doses of sodium nitrite for 48 hours (starting dose at 4.2 µg/kg/hr; maximal dose of 533.8 µg/kg/hr). Clinical, physiologic and laboratory data before, during and after infusion were analyzed.
Findings: The maximal tolerated dose for intravenous infusion of sodium nitrite was 267 µg/kg/hr. Dose limiting toxicity occurred at 446 µg/kg/hr. Toxicity included a transient asymptomatic decrease of mean arterial blood pressure (more than 15 mmHg) and/or an asymptomatic increase of methemoglobin level above 5%. Nitrite, nitrate, S-nitrosothiols concentrations in plasma and whole blood increased in all subjects and returned to preinfusion baseline values within 12 hours after cessation of the infusion. The mean half-life of nitrite estimated at maximal tolerated dose was 45.3 minutes for plasma and 51.4 minutes for whole blood.
Conclusion: Sodium nitrite can be safely infused intravenously at defined concentrations for prolonged intervals. These results should be valuable for developing studies to investigate new NO treatment paradigms for a variety of clinical disorders, including cerebral vasospasm after subarachnoid hemorrhage, and ischemia of the heart, liver, kidney and brain, as well as organ transplants, blood-brain barrier modulation and pulmonary hypertension.
Clinical trial registration information: http://www.clinicaltrials.gov; NCT00103025.
Conflict of interest statement
Competing Interests: A patent titled “Treatment of Specific Cardiovascular Conditions with Nitrite” has been granted for the following co-inventors: Mark T. Gladwin, Alan N. Schechter, Christian Hunter, Ryszard M. Pluta, and Edward H. Oldfield. This research was performed under a cooperative research and development agreement between the National Institute of Neurological Disorders and Stroke at the National Institutes of Health and Hope Pharmaceuticals, Inc. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials.
Figures
References
- Furchgott R, Zawadzki J. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373–376.
- Pepke-Zaba J, Higenbottam T, Dinh-Xuan A, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet. 1991;338:1173–1174.
- Hunter C, Dejam A, Blood A, Shields H, Kim-Shapiro D, et al. Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nat Med. 2004;10:1122–1127.
- Afshar J, Pluta R, Boock R, Thompson B, Oldfield E. Effect of intracarotid nitric oxide on primate cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg. 1995;83:118–122.
- Egemen N, Turker RK, Sanlidilek U, Zorlutuna A, Bilgic S, et al. The effect of intrathecal sodium nitroprusside on severe chronic vasospasm. Neurol Res. 1993;15:310–315.
- Iida S, Chu Y, Francis J, Weiss RM, Gunnett CA, et al. Gene transfer of extracellular superoxide dismutase improves endothelial function in rats with heart failure. Am J Physiol Heart Circ Physiol. 2005;289:H525–532.
- Mason R, Pluta R, Walbridge S, Oldfield E, Boock R. Production of reactive oxygen species after reperfusion in vitro and in vivo: protective effect of nitric oxide. J Neurosurg. 2000;93:99–107.
- Nagasaka Y, Fernandez BO, Garcia-Saura MF, Petersen B, Ichinose F, et al. Brief periods of nitric oxide inhalation protect against myocardial ischemia-reperfusion injury. Anesthesiology. 2008;109:675–682.
- Pluta R, Oldfield E, Boock R. Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage. J Neurosurg. 1997;87:746–751.
- Pluta R, Rak R, Wink D, Oldfield E, Watson J. Effects of nitric oxide on reactive oxygen species production and infarct size following brain reperfusion injury. Neurosurgery. 2001;48:884–892.
- Weyerbrock A, Walbridge S, Pluta RM, Saavedra JE, Keefer LK, et al. Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas. J Neurosurg. 2003;99:728–737.
- Thomas J, Rosenwasser R. Reversal of severe cerebral vasospasm in three patients after aneurysmal subarachnoid hemorrhage: initial observations regarding the use of intraventricular sodium nitroprusside in humans. Neurosurgery. 1999;44:48–57.
- Liu X, Miller M, Joshi H, Sadowska-Krowicka H, Clark D, et al. Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem. 1998;273:18709–18713.
- Ignarro L. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol. 1990;30:535–560.
- Gow J, Stamler J. Reactions between nitric oxide and haemoglobin under physiological conditions. Nature. 1998;391:169–173.
- Gladwin M, Shelhamer J, Schechter A, Pease-Fye M, Waclawiw M, et al. Role of circulating nitrite and S-nitrosohemoglobin in the regulation of regional blood flow in humans. Proc Natl Acad Sci U S A. 2000;97:11482–11487.
- Cosby K, Partovi K, Crawford J, Patel R, Reirter C, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nature Medicine. 2003:1498–1505.
- Furchgott R, Bhadrakom S. Reactions of strips of rabbit aorta to epinephrine, isopropylarterenol, sodium nitrite and other drugs. J Pharmacol Exp Ther. 1953;108:129–143.
- Doyle M, Hoekstra J. Oxidation of nitrogen oxides by bound dioxygen in hemoproteins. J Inorg Biochem. 1981;14:351–358.
- Rodriguez J, Maloney RE, Rassaf T, Bryan NS, Feelisch M. Chemical nature of nitric oxide storage forms in rat vascular tissue. Proc Natl Acad Sci U S A. 2003;100:336–341.
- Gladwin MT, Kim-Shapiro DB. The functional nitrite reductase activity of the heme-globins. Blood. 2008;112:2636–2647.
- Pluta RM, Dejam A, Grimes G, Gladwin MT, Oldfield EH. Nitrite infusions prevent cerebral artery vasospasm in a primate model of subarachnoid aneurismal hemorrhage. JAMA. 2005;293:1477–1484.
- Duranski M, Greer J, Dejam A, Sathya J, Hogg N, et al. Cytoprotective effects of nitrite during ischemia-reperfusion of the heart and liver. JCI. 2005;115:1232–1240.
- Jung KH, Chu K, Ko SY, Lee ST, Sinn DI, et al. Early intravenous infusion of sodium nitrite protects brain against in vivo ischemia-reperfusion injury. Stroke. 2006;37:2744–2750.
- Webb A, Bond R, McLean P, Uppal R, Benjamin N, et al. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. Proc Natl Acad Sci USA. 2004;101:13683–13688.
- Dejam A, Hunter CJ, Tremonti C, Pluta RM, Hon YY, et al. Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation. 2007;116:1821–1831.
- Hon YY, Sun H, Dejam A, Gladwin MT. Characterization of erythrocytic uptake and release and disposition pathways of nitrite, nitrate, methemoglobin, and iron-nitrosyl hemoglobin in the human circulation. Drug Metab Dispos. 2010;38:1707–1713.
- Pelletier MM, Kleinbongard P, Ringwood L, Hito R, Hunter CJ, et al. The measurement of blood and plasma nitrite by chemiluminescence: pitfalls and solutions. Free Radic Biol Med. 2006;41:541–548.
- Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov. 2008;7:156–167.
- Schatlo B, Henning EC, Pluta RM, Latour LL, Golpayegani N, et al. Nitrite does not provide additional protection to thrombolysis in a rat model of stroke with delayed reperfusion. J Cereb Blood Flow Metab. 2007;28:482–489.
- Sinha SS, Shiva S, Gladwin MT. Myocardial protection by nitrite: evidence that this reperfusion therapeutic will not be lost in translation. Trends Cardiovasc Med. 2008;18:163–172.
- Ignarro L. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol. 2002;53:503–514.
- Kelm M. Nitric oxide metabolism and breakdown. Biochim Biophys Acta. 1999;1411:273–289.
- Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci U S A. 1992;89:7674–7677.
- Gladwin M, Crawford J, Patel R. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Rad Biol Med. 2004;36:707–716.
- Dejam A, Hunter CJ, Schechter AN, Gladwin MT. Emerging role of nitrite in human biology. Blood Cells Mol Dis. 2004;32:423–429.
- Bryan N, Rassaf T, Maloney R, Rodriquez C, Saijo F, et al. Cellular targets and mechanism of nitros(yl)ation: An insight into their nature and kinetics in vivo. PNAS. 2004;101:4308–4313.
- Sadamitsu D, Kuroda Y, Nagamitsu T, Tsuruta R, Inoue T, et al. Cerebrospinal fluid and plasma concentrations of nitric oxide metabolites in postoperative patients with subarachnoid hemorrhage. Crit Care Med. 2001;29:77–79.
- Suzuki M, Asahara H, Endo S, Inada K, Doi M, et al. Increased levels of nitrite/nitrate in the cerebrospinal fluid of patients with subarachnoid hemorrhage. Neurosurg Rev. 1999;22:96–98.
- Woszczyk A, Deinsberger W, Boker A-K. Nitric oxide metabolities in cisternal CSF correlate with cerebral vasospasm with a subarachnoid hemorrhage. Acta Neurochir. 2003;145:257–264.
- Pluta R, Thompson B, Dawson T, Snyder S, Oldfield E. Loss of Nitric Oxide synthase immunoreactivity in cerebral vasospasm. J Neurosurg. 1996;84:648–654.
- Pluta R, Afshar J, Boock R, Oldfield E. Temporal changes in perivascular concentrations of oxyhemoglobin, deoxyhemoglobin and, methemoglobin in subarachnoid hemorrhage. J Neurosurg. 1998;88:557–561.
- Hashi K, Mayer J, Shinmaru S, Welch K, Teraura T. Cerebral hemodynamic and metabolic changes after subarachnoid hemorrhage. J Neurol Sci. 1972;17:1–14.
- Khaldi A, Zauner A, Reinert M, Woodward J, Bullock M. Measurements of nitric oxid and brain tissue oxygen tension in patients after severe subarachnoid hemorrhage. Neurosurgery. 2001;49:33–40.
- Grau M, Hendgen-Cotta UB, Brouzos P, Drexhage C, Rassaf T, et al. Recent methodological advances in the analysis of nitrite in the human circulation: nitrite as a biochemical parameter of the L-arginine/NO pathway. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:106–123.
- Lauer T, Preik M, Rassaf T, Strauer B, Deussen A, et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci USA. 2001;98:12814–12819.
- MacArthur PH, Shiva S, Gladwin MT. Measurement of circulating nitrite and S-nitrosothiols by reductive chemiluminescence. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:93–105.
- Dejam A, Hunter CJ, Pelletier MM, Hsu LL, Machado RF, et al. Erythrocytes are the major intravascular storage sites of nitrite in human blood. Blood. 2005;106:734–739.
- Gladwin M, Schechter A, Kim-Shapiro D, Patel R, Hogg N, et al. The emerging biology of the nitrite anion. Nature Chem Biol. 2005;1:1–7.
- Tsikas D. Measurement of nitric oxide synthase activity in vivo and in vitro by gas chromatography-mass spectrometry. In: Hassad A, editor. Nitric oxide protocols. Totowa, NJ: Humana Press; 2004. pp. 81–103.
- Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17:1278–1283.
Source: PubMed